NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.01. View Eiger Biopharmaceuticals' Earnings History.

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eiger Biopharmaceuticals.

5 brokers have issued twelve-month target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $35.00. On average, they anticipate Eiger Biopharmaceuticals' share price to reach $24.68 in the next twelve months. This suggests a possible upside of 113.9% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

Media coverage about EIGR stock has been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 416,500 shares, a drop of 12.4% from the January 15th total of 475,400 shares. Based on an average trading volume of 195,200 shares, the short-interest ratio is currently 2.1 days. Approximately 1.9% of the company's shares are short sold. View Eiger Biopharmaceuticals' Current Options Chain.

Some companies that are related to Eiger Biopharmaceuticals include Krystal Biotech (KRYS), Aerie Pharmaceuticals (AERI), Adverum Biotechnologies (ADVM), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), Vericel (VCEL), Oyster Point Pharma (OYST), Sangamo Therapeutics (SGMO), Cellectis (CLLS), Proteon Therapeutics (PRTO), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY) and Aptose Biosciences (APTO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE) and Catalyst Pharmaceuticals (CPRX).

Eiger Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (5.05%), Farallon Capital Management LLC (4.47%), EcoR1 Capital LLC (1.83%), State Street Corp (1.81%), Geode Capital Management LLC (1.24%) and P.A.W. Capital Corp (0.59%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

EIGR stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BVF Inc. IL, Broadfin Capital LLC, Renaissance Technologies LLC, P.A.W. Capital Corp, Credit Suisse AG, Farallon Capital Management LLC and Trellus Management Company LLC. View Insider Buying and Selling for Eiger Biopharmaceuticals.

EIGR stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, J. Goldman & Co LP, California Public Employees Retirement System, Sanders Morris Harris LLC, Tocqueville Asset Management L.P., Connor Clark & Lunn Investment Management Ltd., Bank of America Corp DE and State Street Corp. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $11.54.

Eiger Biopharmaceuticals has a market capitalization of $282.73 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]